CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Garry Menzel, Ph.D., as Executive Vice President of Corporate Development and Finance. Dr. Menzel brings a very strong background in global biotechnology finance practices to Regulus.
